VYT.MC Vytrus Biotech S.A.
- Market cap
- EUR 108M
- P/E
- 26.0x
- P/B
- 8.33x
- ROE
- 28.1%
- Dividend yield
- -
- Fundamental score
- 3.2/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is VYT.MC undervalued?
Graham numberThe Graham number of Vytrus Biotech S.A. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vytrus Biotech S.A. fundamental analysis
14 of 22 checks passedROE 2/2
High return on equity (28.1%), above 20%.
ROA 1/1
Return on assets (19.8%) is above the industry median (-1.9%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (184.0%) is above the 5-year average (66.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (184.0%) is above the industry median (41.0%).
Revenue Growth 2/2
Revenue grew 31.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (15.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (26.0x) is above the market median (16.3x).
PE vs Industry 0/1
PE (26.0x) is above the industry median (18.6x).
PBV 0/1
Price to book (8.3x) is above the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 216.7, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.39, growth is cheap.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vytrus Biotech S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum …
Full company profileVytrus Biotech S.A. financial statements
Vytrus Biotech S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.70M | 2.80M | 3.68M | 3.74M | 5.04M | 8.37M |
| Gross Profit | 1.50M | 2.38M | 3.03M | 4.35M | 5.50M | 8.83M |
| Operating Income | 208K | 430K | 645K | 454K | 1.00M | 3.18M |
| EBITDA | - | - | 1.34M | 1.18M | 1.83M | 4.16M |
| Net Income | 217K | 450K | 605K | 545K | 1.02M | 2.90M |
| EPS | 0.03 | 0.06 | 0.09 | 0.08 | 0.14 | 0.39 |
| Balance Sheet | ||||||
| Total Assets | 6.21M | 7.18M | 8.00M | 9.31M | 11.1M | 14.7M |
| Total Liabilities | 2.60M | 2.93M | 3.25M | 4.02M | 3.84M | 4.35M |
| Shareholders' Equity | 3.61M | 4.25M | 4.75M | 5.29M | 7.29M | 10.3M |
| Cash & Short-term Investments | 1.09M | 1.28M | 725K | 1.10M | 2.53M | 3.38M |
| Cash Flow | ||||||
| Operating Cash Flow | -132K | 448K | 226K | 904K | 1.84M | 3.90M |
| Capital Expenditure | 235K | 272K | 494K | 1.17M | 1.20M | 2.68M |
| Free Cash Flow | - | 176K | -269K | -262K | 640K | 1.22M |
| Ratios | ||||||
| ROE | 6.0% | 10.6% | 12.7% | 10.3% | 14.0% | 28.1% |
| ROA | 3.5% | 6.3% | 7.6% | 5.9% | 9.2% | 19.8% |
| Net Profit Margin | 12.7% | 16.0% | 16.4% | 14.6% | 20.2% | 34.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vytrus Biotech S.A. dividends
Vytrus Biotech S.A. has not paid dividends in the last 6 fiscal years.
Who owns Vytrus Biotech S.A.
- Insiders 64.47%
- Institutions 1.28%
- Public & others 34.25%
- Shares outstanding 7.52M
- Free float 3.77M
Vytrus Biotech S.A. company profile
- Company name
- Vytrus Biotech S.A.
- Ticker
- VYT.MC
- ISIN
- ES0105618005
- Exchange
- Madrid Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 121 Sant Gaietà, Barcelona, Spain, 08221
- Phone
- 34 93 127 81 06
- Website
- vytrus.com
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. The company also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage. In addition, it offers Photobiome, a prebiotic active that fights the skin photoageing process; Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Olea Vitae, a cellular oil against ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; and Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins. Further, the company provides technology solutions, such as plasma rich in cell factors; phyto-peptidic, phyto-lipidic, and phyto-glucidic fractions; and phyto-cell fusions, as well as Vytrus TV to create an audiovisual space with added value for cosmetic formulation. It exports its products. Vytrus Biotech, S.A. was incorporated in 2009 and is headquartered in Barcelona, Spain.
Vytrus Biotech S.A. management
10- Mr. Albert Jane FontCo-Founder, Co-CEO, President, Member of Management Board & Director
- Mr. Oscar Exposito TarresCo-Founder, Co-CEO, C.S.O, Member of Management Board & Director
- Mr. Jordi Rovira MartinezCFO, Member of Management Board, Secretary of the Board & Director
- Mr. Daniel RobustilloSales Director & Member of Management Board
- Mr. Manel LopezCOO & Member of Management Board
- Ms. Sara LaplanaExecutive CSO & Member of Management Board
- Gloria RuizAccounting Director
- Alejandro GuiradoCommunication & Marketing Manager
- Conxita RusinesESG & People Wellbeing Manager
- Marta RomeroFinance Controller